Related Experiment Videos
Stroke in children
Teresa M Carlin1, Arjun Chanmugam
1Johns Hopkins Hospital, 600 North Wolfe Street, Marburg B187A, Baltimore, MD 21287-2080, USA. TCarlin@JHMI.edu
Insights
Pediatric stroke, though rare, disproportionately affects children with sickle cell or congenital heart disease. Early recognition and defined treatment protocols are crucial to reduce adverse outcomes in childhood stroke.
Area of Science:
- Neurology
- Pediatrics
- Hematology
Background:
- Childhood stroke is a rare but serious condition.
- Children with sickle cell disease and congenital heart disease face increased vulnerability.
- Delayed recognition by healthcare providers and families often hinders timely intervention.
Purpose of the Study:
- To highlight the challenges in pediatric stroke research, including the lack of large multicentered trials.
- To emphasize the need for defined treatment options to reduce adverse outcomes like death and recurrence.
- To discuss the current controversial use of treatment strategies extrapolated from adult literature.
Main Methods:
- Review of existing literature on pediatric stroke.
- Analysis of challenges in conducting large-scale pediatric stroke trials.
- Examination of current treatment protocols and their limitations.
Main Results:
- Pediatric stroke trials are notably absent due to rarity and diverse etiologies.
- Treatment protocols are primarily adapted from adult stroke management.
- The efficacy and safety of therapies like thrombolysis, aspirin, and anticoagulation in children remain controversial.
Conclusions:
- There is a critical need for dedicated pediatric stroke research and evidence-based treatment guidelines.
- Improved diagnostic awareness and standardized protocols are essential for better patient outcomes.
- Further investigation is required to establish optimal therapeutic strategies for childhood stroke.
Abstract:
Childhood stroke is an infrequent occurrence. Children with sickle cell disease and congenital heart disease are particularly vulnerable. The recognition of stroke in children, unlike adults, is typically delayed by healthcare providers and family members. Large, multicentered pediatric stroke trials are absent in the literature. These studies are difficult to perform because the event is rare and the causes are numberous. Adverse outcomes such as death and reoccurrence could be reduced with defined treatment options. Pediatric stroke protocols are largely extrapolated from the adult literature. The use of treatment strategies such as thrombolytic therapy, aspirin, and anticoagulation are controversial at present.